Platelet Rich Fibrin Versus Platelet Rich Plasma for Microneedling Treatment of Facial Photoaging

Launched by CHANG GUNG MEMORIAL HOSPITAL · Jun 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two treatments—platelet-rich plasma (PRP) and platelet-rich fibrin (PRF)—to see which one is more effective and safe for improving signs of photoaging on the face. Photoaging refers to skin damage caused by sun exposure, which can lead to wrinkles, spots, and a rough texture. Participants in the study will receive both treatments: one side of their face will be treated with PRP and the other with PRF, with three sessions of injections spaced one month apart.

To be eligible for the trial, participants should be at least 20 years old and have symmetrical signs of facial photoaging. However, individuals with certain health conditions, such as blood disorders or recent cosmetic procedures, won't be able to participate. Throughout the study, participants will have their skin assessed before each treatment and again one and three months after completing the sessions to track improvements. This trial aims to provide valuable insights into the best treatment options for those looking to address photoaging.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Men or female patients older than 20 years old with facial photoaging (Glogau Scale type II)
• • 2. The photoaging severity of bilateral face is symmetric.
• Exclusion Criteria:
• • 1. Patients with thrombocytopenia, coagulopathy, hematopoietic malignancy.
• • 2. Patients with severe inflammation over treated area, malignancy, keloid, or poor wound healing history.
• • 3. Patients had received laser, radiofrequency, ultherapy over treated area within 6 months.
• • 4. Patients had received botulism or filler injection over treated area within 12 months.
• • 5. Patients had received plastic surgery over treated area within 12 months.
• • 6. Patients had severe psychiatric disorders with poor control.
• • 7. Patients with other diseases which are not suitable for receiving platelet rich plasma (PRP) or platelet rich fibrin (PRF) therapy.